Treatment eligibility in hepatitis B: a call for better linkage to optimal care

Affiliations

¹ Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Division of Gastroenterology and Hepatology, National University Health System, Singapore.
² Department of Epidemiology and Population Health, Stanford University, Palo Alto, CA, USA; Division of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, CA 94304, USA. Electronic address: mindiehn@stanford.edu.

Comment

Daniel Q Huang et al. Lancet Gastroenterol Hepatol. 2021 Mar.

. 2021 Mar;6(3):160.

doi: 10.1016/S2468-1253(20)30391-5.

¹ Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Division of Gastroenterology and Hepatology, National University Health System, Singapore.
² Department of Epidemiology and Population Health, Stanford University, Palo Alto, CA, USA; Division of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, CA 94304, USA. Electronic address: mindiehn@stanford.edu.

No abstract available

Comment on

Estimating the proportion of people with chronic hepatitis B virus infection eligible for hepatitis B antiviral treatment worldwide: a systematic review and meta-analysis.
Tan M, Bhadoria AS, Cui F, Tan A, Van Holten J, Easterbrook P, Ford N, Han Q, Lu Y, Bulterys M, Hutin Y. Tan M, et al. Lancet Gastroenterol Hepatol. 2021 Feb;6(2):106-119. doi: 10.1016/S2468-1253(20)30307-1. Epub 2020 Nov 14. Lancet Gastroenterol Hepatol. 2021. PMID: 33197397 Free PMC article.